Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib ± Apatinib in Recurrent Ovarian Cancer
CTR20201749Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of fluzoparib, Rivoceranib in ovarian cancer (OC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), Endometrioid Cystadenocarcinoma, sponsored by Hengrui Therapeutics. Started Sep 2020; status: completed.
02
Drugs
fluzoparibRivoceranib
03
Conditions
ovarian cancer (OC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)Endometrioid Cystadenocarcinoma
Beyond the preview
Go deeper on CTR20201749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201749.